Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Leerink Global Healthcare Conference Transcript

Feb 26, 2020 / 07:00PM GMT
Release Date Price: R$42.89 (-2.59%)
Danielle Joy Antalffy
SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior Analyst

Okay. I guess we have to start. Okay. Hi. Good afternoon, everyone. Thanks for joining us.

My name is Danielle Antalffy. I'm one of the senior med tech analysts here at SVB Leerink. And we are very lucky for the second year in a row to have Ashley McEvoy from Johnson & Johnson. She's Head of the Devices Group.

Before we get started, we also have Matt Stuckley from Investor Relations, and he will read forward-looking statements.

Matthew Stuckley
Johnson & Johnson - Senior Director of IR

Thanks, Danielle. Good afternoon, everyone.

Please be aware that some statements made today may be considered forward-looking or utilize non-GAAP measures. Please refer to our SEC filings, in particular our 10-K, which discuss the risks and uncertainties around forward-looking statements as well as our website at investor.jnj.com for reconciliations to comparable GAAP measures. Finally, any remarks regarding financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot